Results 181 to 190 of about 15,981,489 (330)

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

open access: yesNew England Journal of Medicine, 2016
B. Feagan   +26 more
semanticscholar   +1 more source

The ‘Cross‐Trust’ Histopathology Multidisciplinary Team: Report of meeting outputs and impact on paediatric inflammatory bowel disease management in a UK tertiary centre

open access: yesJPGN Reports, EarlyView.
Abstract Objectives To evaluate the outputs and clinical impact of a Cross‐Trust Histopathology Multidisciplinary Team (MDT) created to support diagnostic clarification and management of complex paediatric inflammatory bowel disease (IBD) cases, particularly during transition to adult services.
Valeria Dipasquale   +5 more
wiley   +1 more source

Adalimumab for the treatment of Crohn’s disease

open access: yes, 2008
Andrea Cassinotti, Sandro Ardizzone, Gabriele Bianchi PorroDepartment of Clinical Sciences, Chair of Gastroenterology, “Luigi Sacco” University Hospital, Milan, ItalyIntroduction: Crohn’s disease (CD) is a chronic ...
Gabriele Bianchi Porro   +2 more
core  

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

open access: yesJPGN Reports, EarlyView.
Abstract Objectives To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy. Methods A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January ...
Cher Wei Chuah   +9 more
wiley   +1 more source

Infliximab, azathioprine, or combination therapy for Crohn's disease.

open access: yesNew England Journal of Medicine, 2010
J. Colombel   +12 more
semanticscholar   +1 more source

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Adalimumab biosimilars are as safe and effective compared to the originator. Adult patients with inflammatory bowel disease (IBD) who switched to a biosimilar have comparable outcomes, but pediatric data are limited. This study evaluates clinical outcomes of children and young adults with IBD following a nonmedical, insurance‐driven
Daniel Himelstein   +5 more
wiley   +1 more source

A joint transdisciplinary approach for paediatric inflammatory bowel disease: Integrating nursing, dietetic and psychological support

open access: yesJPGN Reports, EarlyView.
Abstract Paediatric inflammatory bowel disease (pIBD) is a long‐term, immune‐mediated condition characterised by fluctuating gastrointestinal symptoms, nutritional risk and psychosocial difficulties. Although multidisciplinary team (MDT) support is considered the gold standard, there is considerable variation in how it is delivered, and it remains ...
King‐Chi Yau, Laura Tesser, Kay Crook
wiley   +1 more source

Home - About - Disclaimer - Privacy